Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04663321 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)
A Phase 2 study, sponsored by Merck Sharp & Dohme.
- Terminated
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
NCT04663321 is a Phase 2 study that was terminated before completion, run by Merck Sharp & Dohme. The registered enrollment target is 99 participants.
The verdict
NCT04663321, a Phase 2 study, was terminated before completion, sponsored by Merck Sharp & Dohme.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess the efficacy and safety of daily and intermittent dosing of MK-1942 compared to placebo among participants with Treatment-Resistant Depression (TRD) on a stable course of antidepressant therapy. The dual primary hypotheses of the study are that the daily MK-1942 treatment or intermittent MK-1942 treatment are superior to placebo in reducing Montgomery-Asberg Depression Rating Scale (MADRS) score.
Interventions
- DRUG Placebo
- DRUG MK-1942
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2021-05-20 |
| Est. Completion | 2023-09-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04663321
The ClinicalTrials.gov registry entry for NCT04663321 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04663321 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04663321 about?
NCT04663321 is a clinical study titled "Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)". The main purpose of this study is to assess the efficacy and safety of daily and intermittent dosing of MK-1942 compared to placebo among participants with Treatment-Resistant Depression (TRD) on a stable course of antidepressant therapy. The dual primary hypotheses of the study are that the daily M...
What is the current status of trial NCT04663321?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2021-05-20. Estimated completion is 2023-09-08.
What interventions are being tested in trial NCT04663321?
The interventions under investigation include: Placebo (DRUG), MK-1942 (DRUG).
Who is sponsoring clinical trial NCT04663321?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.